Primary Site >> Stomach Cancer
Gene >> ERCC1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. PMID: 9440758 Ref: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. PMID: 9861196 |
Ref: Polymorphisms in DNA repair genes and associations with cancer risk. PMID: 12496039 |
Ref: Pharmacogenetics of stomach cancer. PMID: 12914384 |
Ref: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. PMID: 15837757 |
Ref: Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. PMID: 16622263 Ref: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. PMID: 17163161 Ref: Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. PMID: 19771254 |
Ref: Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. PMID: 17256130 Ref: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. PMID: 17322540 Ref: Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. PMID: 17607914 Ref: Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. PMID: 17617021 |
Ref: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. PMID: 18231104 Ref: ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. PMID: 18362936 Ref: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. PMID: 18402708 Ref: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. PMID: 18442042 Ref: Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. PMID: 18751380 Ref: ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. PMID: 19009659 Ref: [ERCC1 mRNA expression levels and outcome of gastric cancer patients receiving oxaliplatin-based chemotherapy]. PMID: 19094468 |
Ref: Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. PMID: 19247656 Ref: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. PMID: 19259093 Ref: Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. PMID: 19332728 Ref: Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer PMID: 19513514 Ref: CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. PMID: 19822419 |
Ref: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. PMID: 20130877 Ref: BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. PMID: 20331623 Ref: The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines. PMID: 20590442 Ref: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. PMID: 20593954 Ref: Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. PMID: 20622964 Ref: Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer. PMID: 20817763 Ref: Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. PMID: 20878069 Ref: [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. PMID: 21029695 Ref: Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer. PMID: 22993546 |
Ref: Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. PMID: 20503071 Ref: Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. PMID: 21133646 Ref: [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy]. PMID: 21418871 Ref: A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. PMID: 21482024 Ref: Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III beta-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. PMID: 23358102 |
Ref: Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. PMID: 22266184 Ref: Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. PMID: 22444164 Ref: Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. PMID: 23020798 Ref: Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. PMID: 23166636 Ref: Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. PMID: 23317227 |
Ref: A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. PMID: 23338051 Ref: Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term. PMID: 23355039 Ref: The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. PMID: 23426424 Ref: A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. PMID: 23517622 Ref: Genetic polymorphisms of ERCC1118, XRCC1399 and GSTP1105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatinbased adjuvant chemotherapy. PMID: 23604281 Ref: ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. PMID: 23645290 Ref: A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. PMID: 23680703 Ref: Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. PMID: 23719746 Ref: Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors. PMID: 23762305 Ref: [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology]. PMID: 23828702 Ref: Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. PMID: 23884439 Ref: ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PMID: 24023723 Ref: Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. PMID: 24053422 Ref: Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population. PMID: 24125975 Ref: DNA repair capacity in peripheral blood lymphocytes predicts efficacy of platinum-based chemotherapy in patients with gastric cancer. PMID: 24175850 |
Ref: PEITC reverse multi-drug resistance of human gastric cancer SGC7901/DDP cell line. PMID: 23956061 Ref: Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. PMID: 24300914 Ref: Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. PMID: 24318989 Ref: A nonsense mutation in the Xeroderma pigmentosum complementation group F (XPF) gene is associated with gastric carcinogenesis. PMID: 24412486 Ref: [Synergistic interaction between melittin and chemotherapeutic agents and their possible mechanisms: an experimental research]. PMID: 24672950 Ref: ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. PMID: 24699918 Ref: Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population. PMID: 24793015 Ref: Molecular profiling in gastric cancer: examining potential targets for chemotherapy. PMID: 24844210 Ref: The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. PMID: 24870596 Ref: Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. PMID: 24990617 Ref: Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis. PMID: 24994039 Ref: Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. PMID: 25035660 Ref: Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. PMID: 25083297 Ref: Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer. PMID: 25222248 Ref: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients. PMID: 25223338 Ref: Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. PMID: 25366763 Ref: Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China. PMID: 25674197 |
Ref: Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer. PMID: 25542228 Ref: Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. PMID: 25778705 Ref: Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis. PMID: 25780441 Ref: Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. PMID: 25834456 Ref: Retraction note: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients. PMID: 25888862 Ref: Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. PMID: 26097599 Ref: Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. PMID: 26191265 Ref: Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. PMID: 26396673 Ref: Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. PMID: 26499900 Ref: Genetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer. PMID: 26622786 Ref: Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy. PMID: 26662383 Ref: Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients. PMID: 26681216 Ref: Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer. PMID: 26722542 Ref: Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. PMID: 26770441 Ref: Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer. PMID: 26782397 Ref: Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. PMID: 26823845 |
Ref: Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy. PMID: 26314858 Ref: Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo. PMID: 26802649 Ref: Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer Receiving Platinum-based Chemotherapy. PMID: 27039774 Ref: Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. PMID: 27081844 Ref: Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood. PMID: 27123139 Ref: Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002). PMID: 27142170 Ref: Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer. PMID: 27173253 Ref: Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer. PMID: 27340861 Ref: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. PMID: 27384994 Ref: [Pathological Complete Response of Advanced Gastric Cancer after Docetaxel and S-1 Combination Neoadjuvant Chemotherapy-A Case Report]. PMID: 27431635 Ref: ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. PMID: 27487151 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 Ref: Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo. PMID: 29021019 |
Ref: Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. PMID: 27995989 Ref: Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. PMID: 28056823 Ref: Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer. PMID: 28102711 Ref: Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression. PMID: 28796378 Ref: The intricate interplay between MSI and polymorphisms of DNA repair enzymes in gastric cancer H.pylori associated. PMID: 28927196 |
Ref: Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. PMID: 29125480 Ref: ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations. PMID: 29302191 Ref: Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients. PMID: 29491212 Ref: Genetic variants in the nucleotide excision repair pathway genes and gastric cancer susceptibility in a southern Chinese population. PMID: 29695933 Ref: Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. PMID: 30011079 Ref: Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. PMID: 30282452 |